3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 4
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
3
Stomach Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-Positive Primary Breast Cancer
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
Radiosurgery
23
Radiotherapy
20
Temozolomide
17
Lomustine
9
Bevacizumab
8
Surgical Procedures, Operative
7
Procarbazine
6
Vincristine
5
Nivolumab
5
Memantine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Carboplatin
4
Specimen Handling
3
Sodium Chloride
3
Radiation
3
Methylphenidate
3
Mental Status and Dementia Tests
3
Granulocyte Colony-Stimulating Factor
3
Gefitinib
3
Cyclophosphamide
3
Corticotropin-Releasing Hormone
3
Carmustine
3
icotinib
2
etoposide phosphate
2
efaproxiral
2
X-Rays
2
Tranexamic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Brain Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT04739761
2026-05-12
DESTINY-B12
AstraZeneca
Phase 3
Active not recruiting
506 enrolled
27 charts